A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label multicenter, phase 1-2 study. Following determination of the
recommended AEG35156 dose in combination with carboplatin and paclitaxel in the initial Phase
1 part of this study, additional patients will be enrolled in the Phase 2 part of the study
to assess the activity of the combination in advanced non small cell lung cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Aegera Therapeutics
Treatments:
Albumin-Bound Paclitaxel Carboplatin Paclitaxel X-Linked Inhibitor of Apoptosis Protein